LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042-Reference-Cited by-同舟云学术

LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

Published:2019-12 Issue: Volume:30 Page:xi63-xi64
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Herbst R.S.,Lopes G.,Kowalski D.M.,Kasahara K.,Wu Y.-L.,De Castro G.,Cho B.C.,Turna H.Z.,Cristescu R.,Aurora-Garg D.,Lunceford J.,Kobie J.,Ayers M.,Pietanza M.C.,Piperdi B.,Mok T.S.K.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_11/mdz453.001/31508142/mdz453.001.pdf

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of first‐line immune checkpoint inhibitor and anti‐angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen‐mutant advanced non‐small‐cell lung cancer: a systematic review and network meta‐analysis;Thoracic Cancer;2024-07-31

2. Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer;Human Genetics and Genomics Advances;2024-07

3. Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments;Drugs;2024-04-16

4. Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer;Cancers;2024-04-09

5. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels;Lung Cancer;2024-04